Key Takeaways
- Volume sacrificed, value protected: Revenue grew 8% YoY to ₹686 crores despite a 6–7% volume drop, as the shift toward premium products and raw material pass-through offset weak herbicide and granule sales caused by low rains.
- Gross margin resilience, not yet expansion: H1 gross margin improved ~100 bps to 32.7%, but Q2 slipped to 33.7% from 34.5% YoY; management aims to hold around these levels for the year, with a long-term ambition of ~1% annual improvement.
- Kaeros is the growth engine, doubling next year: The parallel brand crossed ~₹114 crores in H1, is on track for ~₹200 crores stand-alone this fiscal, and management targets a 100% CAGR next year as an all-India network completes in H2.
- Capex cycle nears its end: The Dahej plant completes in Q3 and the Sotanala project wraps next fiscal, after which the major capex cycle will be left behind, promising normalization of interest costs and improved cash flows.
- What to watch next quarter: Whether H2 volume recovery materializes as rabi season begins, the pace of Kaeros’s southern market rollout, and any concrete CDMO contract announcements that would de-risk the ₹500 crore international ambition.
Volume vs Value: The Low-Rain Tradeoff
- Volume drop was weather-driven: A 6–7% volume decline in Q2 stemmed from low rains that hit herbicide and granule applications, with El Nino disrupting both wet crops (sugarcane, paddy) and dry crops (maize, cotton, soybean, chilli).
- Value growth came from premiumization: 4–5% value growth was achieved by selling more new-generation products; farmer interest shifted toward better solutions even as the number of sprays declined, and the Focus Maharatna and Maharatna categories both saw increases.
- Full-year volume will stay negative: Management was explicit that this is not a year of volume growth; value growth will come from a combination of raw material cost pass-through and selling more premium products, with some improvement expected in H2.
Rajesh Aggarwal: "This is not a year of volume growth. We'll just end up doing the value growth because the volume has already suffered because of low rains."
Kaeros: The Parallel Brand Bet
- Rapid scale-up underway: Kaeros did ~₹114 crores in H1, with North, East and West fully opened; the southern market rollout in H2 will make it an all-India network this fiscal, and stand-alone turnover may touch ~₹200 crores.
- Next-year ambition is aggressive: Management plans to double Kaeros from this fiscal’s level, citing a 50%+ CAGR trajectory and stating that 100% CAGR next year “won’t be wrong.”
- Technology backbone is ready: The Beetroot system for Kaeros will be fully operational after Diwali, with trial entries ongoing for two months; more than 55 products are already commercialized, with about 60 expected in the market this year.
- Why a second brand exists: A pipeline of more than 30 patented formulation technologies coming in the next 2–3 years compelled the company to open Kaeros as a parallel brand to handle the volume; products will be divided between the two companies.
Rajesh Aggarwal: "Next year, we can very well plan to double from here."
Capex Endgame & Manufacturing Scale-Up
- Dahej nears completion: The plant is partially capitalized and partially in manufacturing; full completion is expected by December (Q3 FY27), after which it restarts in full swing following a shutdown, with only minor maintenance capex remaining next year.
- Sotanala is the last big piece: Formulation operations are targeted to start in April, with a possible 1–2 month delay to May; technical manufacturing is expected next fiscal, with a vision of Diwali or a December/January fallback.
- Capex cycle conclusion is material: After Sotanala completes, the major capex cycle will be left behind, which management links directly to normalization of interest costs and improved cash flows as utilization of new facilities ramps up.
Rajesh Aggarwal: "After completion of Sotanala project, major capex cycle will be left behind us."
International & CDMO: The Five-Year Bet
- Current base is tiny: International business is about 5% of revenue, which management considers very low versus peers; the majority of export revenue currently comes from white-label formulations, not technicals.
- Technicals are the future growth vector: The company is working on about 15 active ingredients for technical exports, with about 12 technicals filed for registrations in various countries and many already received; growth is expected to come from technicals going forward.
- CDMO is in early innings: Some initial agreements have been signed and one container has been supplied, but management does not count that as a full start; the plan is to build a DCS plant at Sotanala and upgrade Dahej to conduct CDMO activities from both sites, targeting a big way in the next fiscal, with majority Japanese clients.
- The five-year vision is ₹500 crores: Management aspires to grow international business at a 40–50% CAGR from a small base, reaching ₹500 crores in five years, including CDMO, new fluid supplies, and regular exports.
Rajesh Aggarwal: "I wish to grow at a CAGR of not less than 40%, 50% because my base is very small. So let's see how the things progress. But I can say that 5 years down the line, I see my business as INR500 crores from international markets..."
Product Pipeline & R&D Philosophy
- Near-term launches are limited: Spinoace and Granuvia launched this year with lukewarm response due to low pest and disease pressure; no further visible launches remain in the current fiscal, with maybe 1–2 odd ones possible, while 3–5 launches are visible for next fiscal.
- The 30-technology pipeline is the real story: About 30 patented formulation technologies are set to come to market in the next 2–3 years, driving the Focus Maharatna strategy and the need for a parallel brand.
- Nissan collaboration is deepening: The partnership started in 2013 with 2 products and now handles 7, with an eighth product (a new mode-of-action herbicide) to be launched soon; the company is also developing mixtures with Nissan, not just straight products.
- OAT Agrio JV holds a first-of-its-kind asset: The new discovery molecule, described as the first new mode-of-action discovery from India, has had its first application filed for inclusion in the Schedule of the Insecticide Act; clearance is expected in a few months, with a chance to hit the market next fiscal, and visibility of at least three products from this JV.
- R&D is run lean by design: Management believes R&D is to perform, not to show, and aims to do more with lower expenses.
Rajesh Aggarwal: "I believe that R&D is to perform and not to show. So we believe in performance. With lower expenses, we wish to do more R&D."
Margins, Working Capital & Returns
- Gross margin trajectory is a slow grind: H1 gross margin improved ~100 bps to 32.7%, but Q2 slipped to 33.7% from 34.5% YoY; management will try to maintain around the 33% level for the year, with a long-term expectation of ~1% annual improvement on average, targeting best-in-industry levels step by step.
- Working capital stretched further: Working capital days rose to 158 from 151, with net working capital climbing to ~₹1,000 crores from ₹966 crores YoY and ₹828 crores as of March 2026; inventories and debtors remain at elevated levels, and management is focused on improving cash flows going forward.
- Sales returns are high but controlled: Returns are lower than last year because the company was very particular about placements despite a weak season; most returns already came in Q2, and Q3 and Q4 should see normal levels, though visibility on recovering H1 losses is not clear.
- Premium product mix is the margin lever: The target is to touch 70% contribution from premium products, up from 60%+ currently, with margins improving year-on-year; the target will be revised upward after achievement.
Rajesh Aggarwal: "I'm very, very confident that we'll not only grow our top line, we'll grow the bottom line margins also in terms of percentage and in terms of actual numbers."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej plant completion | Plant to be fully completed and restarted in full swing | December (Q3 FY27) |
| Sotanala formulation start | Formulation business to begin operations | April, possible delay to May |
| Sotanala technical manufacturing start | Technical manufacturing to commence | Next fiscal; vision Diwali, fallback December/January |
| Major capex cycle end | Major capex cycle left behind after Sotanala completion | Next fiscal |
| Kaeros all-India network | Southern markets opened, making Kaeros visible across India | H2 of this fiscal |
| Kaeros stand-alone turnover | ~₹200 crores stand-alone | This fiscal |
| Kaeros brand turnover | Cross ₹125 crores | This fiscal |
| Kaeros growth next year | Double from this fiscal's level (100% CAGR possible) | Next fiscal |
| Premium product contribution | Touch 70% of portfolio | No date; target to be revised after achievement |
| International business 5-year target | ₹500 crores from international markets | 5 years |
| OAT Agrio first product launch | First product from JV to hit market | Next fiscal (chance); 2027 target may slip by a few months |
| Gross margin long-term trajectory | ~1% annual improvement on average, step-by-step toward best-in-industry | Ongoing; some years 2–3% jump, some only bps |
| Nissan new herbicide launch | New mode-of-action herbicide launched | This kharif season |
| CDMO scale-up | Build DCS plant at Sotanala, upgrade Dahej; target big way | Next fiscal |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹686 cr, 8% YoY growth vs ₹637 cr in Q2 FY26 |
| H1 FY27 revenue growth | 2% degrowth YoY |
| Gross profit margin | 33.7%, vs 34.5% in Q2 FY26 |
| EBITDA | ₹92.44 cr; EBITDA margin 13.5% |
| Profit after tax | ₹56.17 cr |
| H1 FY27 gross profit margin | 32.7%, ~100 bps improvement vs 31.7% in H1 FY26 |
| H1 FY27 EBITDA | ₹161 cr; EBITDA margin 12.3% |
| H1 FY27 profit after tax | ~₹100 cr |
| Volume growth | Negative, drop of about 6% to 7% YoY |
| Value growth | 4% to 5% YoY |
| Working capital days | 158 days in H1 FY27, vs 151 days in H1 FY26 |
| Net working capital | ~₹1,000 cr as of 30 Sep, vs ₹966 cr as of 30 Sep '25 and ₹828 cr as of 31 Mar '26 |
| Inventory | ₹814 cr as of 30 Sep, vs ₹744 cr |
| Debtors | ₹719 cr as of 30 Sep, vs ₹643 cr |
| Kaeros total sales H1 FY27 | ~₹114 cr; brand gross turnover ~₹75 cr |
| Kaeros full-year brand turnover target | Cross ₹125 cr; stand-alone might touch ~₹200 cr |
| Premium products contribution | 60%+ of B2C portfolio; target to touch 70% |
| International business contribution | ~5% of revenue |
| B2B business | ~₹400 cr+ |
| Farmer meetings in H1 | More than 18,000 |
| Demonstrations in H1 | More than 9,000 |
| Farmers met in H1 | More than 2.5 lakh |
| ICS plots | ~70 across 4 crops, doubled from ~30 last year |
| R&D expense booked | ~₹12 cr annually |